ArticleWorld journal of nuclear medicine

Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases.

John Buscombe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.